Skip to main content
Premium Trial:

Request an Annual Quote

People: Byron Hewett, Larry Gold

Premium

SomaLogic has named Byron Hewett as CEO. Hewett takes replaces Larry Gold, who will continue serving the Boulder, Colo.-based company as chairman of the board. Gold will also work as a full-time adviser, SomaLogic said.

Gold co-founded SomaLogic in 2000 and had served as CEO until Hewett's appointment. In a statement, Gold said that while the protein biomarker discovery and clinical diagnostics company has been successful in its initial goals, it needed "additional leadership with the deep business experience and knowledge to take SomaLogic to the next level," and that Hewett is "the leader we need at this critical stage of our company's growth."

Hewett most recently was chairman and CEO of Biobehavioral Diagnostics. He previously was president and CEO of Immunicon and senior vice president of sales and marketing and general manager, North America, for Qiagen. He also has held leadership posts at Abbott Diagnostics, Chiron/Bayer, and BioCircuits.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.